Atlas Trials

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Clinical trial NCT05208853 · UNKNOWN

Trial details

NCT number
NCT05208853
Sponsor
Zhejiang University
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
Hodgkin LymphomaNK/T Cell LymphomaPeripheral T Cell Lymphoma, UnspecifiedAngioimmunoblastic T-cell LymphomaAnaplastic Large Cell LymphomaDiffuse Large B Cell LymphomaMediastinal B-Cell Diffuse Large Cell LymphomaGray Zone Lymphoma
Start date
2022-02-10
Primary completion
2022-02-10
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.